Publications by authors named "Mathias J Rummel"

Claim this Profile
H
Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384).
Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias J Rummel

Cancers (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
Heiner Zimmermann, Christian Koenecke, Martin H Dreyling, Christiane Pott, Ulrich Dührsen, Mathias J Rummel

Leukemia· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
Mathias J Rummel, Ann Janssens, David MacDonald, Mary-Margaret Keating, Jan M Zaucha

Br J Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.
Richard Vollenberg, Rabie Jouni, Peter A A Norris, Monika Burg-Roderfeld, Nina Cooper, Mathias J Rummel

Haematologica· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Fabian Zohren, Ingmar Bruns, Sabrina Pechtel, Thomas Schroeder, Roland Fenk, Mathias J Rummel

Blood· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, G Andre Banat, Ulrich von Grünhagen

Lancet· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP).
Abderrahim Najaoui, Tamam Bakchoul, Johanna Stoy, Gregor Bein, Mathias J Rummel

Eur J Haematol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine's emerging role in the management of lymphoid malignancies.
Mathias J Rummel, Stephanie A Gregory

Semin Hematol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana.
Myron S Czuczman, Mathias J Rummel

Clin Adv Hematol Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Hairy cell leukemia: Part I: disease pattern and common therapy].
Jürgen Barth, Mathias J Rummel

Med Monatsschr Pharm· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Hairy cell leukemia: Part II: therapy with cladribine].
Jürgen Barth, Mathias J Rummel

Med Monatsschr Pharm· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine: rebirth of an old drug.
Bruce D Cheson, Mathias J Rummel

J Clin Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
Mathias J Rummel

Semin Hematol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.
Markus Jensen, Andreas Engert, Florian Weissinger, Wolfgang Knauf, Eva Kimby, Mathias J Rummel

Invest New Drugs· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Mathias J Rummel, Salah E Al-Batran, Soo-Z Kim, Manfred Welslau, Ralf Hecker

J Clin Oncol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
James O Armitage, Kensei Tobinai, Dieter Hoelzer, Mathias J Rummel

Int J Hematol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Salah-Eddin Al-Batran, Akin Atmaca, Susanna Hegewisch-Becker, Dirk Jaeger, Sabine Hahnfeld, Mathias J Rummel

J Clin Oncol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered apoptosis pathways in mantle cell lymphoma.
Mathias J Rummel, Sven de Vos, Dieter Hoelzer, H Phillip Koeffler, Wolf-K Hofmann

Leuk Lymphoma· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro studies with bendamustine: enhanced activity in combination with rituximab.
Mathias J Rummel, Kai U Chow, Dieter Hoelzer, Paris S Mitrou, Eckhart Weidmann

Semin Oncol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Mathias J Rummel, Paris S Mitrou, Dieter Hoelzer

Semin Oncol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.
Kai U Chow, Simone Boehrer, Joerg Bojunga, Manuela Stieler, Mathias J Rummel

Leuk Lymphoma· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Kai U Chow, Wolf Daniel Sommerlad, Simone Boehrer, Bernd Schneider, Gernot Seipelt, Mathias Johannes Rummel

Haematologica· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis